Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

December 31, 2012

Conditions
Hepatitis C Virus
Interventions
DRUG

BMS-790052

Film coated tablet, Oral, 20 mg, once daily, 24 weeks

DRUG

BMS-790052

Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks

DRUG

Placebo

Film coated tablet, Oral, 0mg, Once daily, 24 weeks

DRUG

peginterferon alfa-2a

Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks

DRUG

ribavirin

Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks

Trial Locations (72)

2000

Local Institution, Prov de Santa Fe

2031

Local Institution, Randwick

2650

Local Institution, Hvidovre

3004

Local Institution, Prahan

3084

Local Institution, Heidelberg

3168

Local Institution, Clayton

5000

Local Institution, Odense

6001

Local Institution, Perth

6160

Local Institution, Fremantle

8200

Local Institution, Aarhus

10468

James J Peters Vamc, The Bronx

11201

James Sungsik Park, M.D. C.N.S.C., Great Neck

12208

Samuel S. Stratton Vamc, Albany

12701

Upper Delaware Valley Infectious Diseases, Pc, Monticello

14186

Local Institution, Stockholm

14642

University Of Rochester Medical Center, Rochester

19104

University Of Pennsylvania, Philadelphia

20099

Local Institution, Hamburg

21093

Johns Hopkins Medical Institutions, Lutherville

21202

Mercy Medical Center, Baltimore

21229

Digestive Disease Associates, P.A., Baltimore

22031

Metropolitan Research, Fairfax

27100

Local Institution, Pavia

28677

Carolinas Center For Liver Disease, Statesville

30625

Local Institution, Hanover

33143

Miami Research Associates, South Miami

36116

Alabama Liver & Digestive Specialists (Alds), Montgomery

37205

Nashville Medical Research Institute, Nashville

44160

Local Institution, Guadalajara

45122

Local Institution, Essen

46202

Indiana University, Indianapolis

53715

Dean Clinic, Madison

54511

Local Institution, Vandœuvre-lès-Nancy

56124

Local Institution, Cisanello (pisa)

60590

Local Institution, Frankfurt

62170

Local Institution, Cuernavaca

63104

Saint Louis University, St Louis

64710

Local Institution, Monterrey

69317

Local Institution, Lyon

70121

Ochsner Clinic Foundation, New Orleans

74135

Healthcare Research Consultants, Tulsa

75013

Local Institution, Paris

75679

Local Institution, Paris

76012

North Texas Research Institute, Arlington

77030

Liver Associates Of Texas, Houston

St. Luke'S Episcopal Hospital - Baylor College Of Medicine, Houston

78215

Alamo Medical Research, San Antonio

80045

Transplant Center And Hepatology Clinic, B-154, Aurora

90048

CLI, Los Angeles

92037

Scripps Clinic, La Jolla

92114

Desta Digestive Disease Medical Center, San Diego

92118

Local Institution, Clichy

94010

Local Institution, Créteil

94110

University Of California At San Francisco, San Francisco

94115

California Pacific Medical Center, San Francisco

94118

Kaiser Permanente Medical Center, San Francisco

06520

Yale University School Of Medicine, New Haven

32610-0277

University Of Florida Hepatology, Gainesville

01105

The Research Institute, Springfield

27599-7584

University Of North Carolina, Chapel Hill, Chapel Hill

02905

University Gastroenterology, Providence

C1121ABE

Local Institution, Ciudad de Buenos Aires

C1181ACH

Local Institution, Ciudad de Buenos Aires

T6G 2B7

Local Institution, Edmonton

V6Z 2K5

Local Institution, Vancouver

V8V 3P9

Local Institution, Victoria

M5G 2N2

Local Institution, Toronto

M5T 2S8

Local Institution, Toronto

06202

Local Institution, Nice

00780

Instituto De Investigacion Cientifica Del Sur, Ponce

00927

Local Institution, San Juan

SE-416 85

Local Institution, Gothenburg

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY